Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use. Recarbrio – which based on ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

That includes antibiotics including amoxicillin and penicillin, according to a U.S. Food and Drug Administration database.

Growing demand for tryptamine APIs stems from their anti-cancer potential, pharmaceutical uses, and role as a neurotransmitter modulator i ...

Merck & Co is enjoying blockbuster revenues ... Getting drugs developed for very rare diseases, and certain drug classes such as antibiotics, is harder as big pharma companies and investors ...

There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

by Merck & Co highlights renewed interest from big pharma in the long-neglected market for antibiotics. Massachusetts-based Cubist is at the forefront of efforts to develop a new generation of ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...